A global review of melanoma follow-up guidelines

Journal of Clinical and Aesthetic Dermatology

Volumn 6, Issue 9, 2013, Pages 18-26

  Trotter, Shannon C ^a   Sroa, Novie ^a   Winkelmann, Richard R ^b   Olencki, Thomas ^a   Bechtel, Mark ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b O'Bleness Memorial Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE; PROTEIN S 100;

AUSTRALIA AND NEW ZEALAND; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CUTANEOUS MELANOMA; DERMATOLOGIST; DISEASE COURSE; DYSPLASTIC NEVUS; EVIDENCE BASED PRACTICE; FAMILY HISTORY; FOLLOW UP; GENERAL SURGERY; HEALTH CARE PERSONNEL; HIGH RISK PATIENT; HUMAN; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG METASTASIS; LYMPH NODE DISSECTION; MEDICAL SPECIALIST; MELANOMA; META ANALYSIS; MICROMETASTASIS; MITOSIS INDEX; NUCLEAR MAGNETIC RESONANCE IMAGING; NURSE PRACTITIONER; OUTPATIENT; OVERALL SURVIVAL; PATIENT EDUCATION; PATIENT PREFERENCE; PHENOTYPE; PHYSICAL EXAMINATION; PHYSICIAN ASSISTANT; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIMARY TUMOR; RECURRENCE RISK; RECURRENT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; SELF EVALUATION; SELF EXAMINATION; SENSITIVITY AND SPECIFICITY; SKIN EXAMINATION; THORAX RADIOGRAPHY; UNITED STATES; WHOLE BODY IMAGING;

EID: 84886740914     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. American Cancer Society. Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013.
2. NCCN Clinical Practice Guidelines in Oncology: Melanoma. 2013. http://www.nccn.org/professionals/physician-gls/pdf/melanoma.pdf. Accessed on January 23, 2013.
3. Linos E, Swetter SM, Cockburn MG, et al. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009;129:1604-1606.
4. Desmond RA, Soong SJ. Epidemiology of malignant melanoma. Surg Clin North Am. 2003;83:1-29.
5. Balch CM, Gershenwald JE, Soong S, et al. Final version of 2009 AJCC Melanoma Staging Guidelines. J Clin Oncol. 2009;27:6199-6206.
6. Dummer R, Hauschild A, Guggenheim M, et al. Melanoma: ESMO Clinical Practice Guidelines of care for the diagnosis, treatment, and follow-up. Ann Oncol. 2010;21(Suppl 5):194-197.
7. Bichakjian CK, Halpern AC, Johnson TM, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2011;65:1032-1047.
8. Marsden JR, Newton-Bishop JA, Burrows L, et al. Revised UK guidelines of care for the management of cutaneous melanoma 2010. Br J Dermatol. 2010;163:238-256.
9. Dummer R, Guggenheim M, Arnold AW, et al. Task Force Skin Cancer. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Swiss Med Wkly. 2011;141:w13320.
10. Garbe C, Hauschild A, Volkenandt M, et al. Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res. 2007;17(6):393-399.
11. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. 2008. www.nhmrc.gov.au/guidelines/publications/cp111. Accessed June 6, 2013.
12. McKenna DB, Marioni JC, Lee RJ, et al. A comparison of dermatologists', surgeons' and general practitioners' surgical management of cutaneous melanoma. Br J Dermatol. 2004;151(3):636-644.
13. Basseres N, Grob JJ, Richard MA, et al. Cost-effectiveness of surveillance of Stage I melanoma: a retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatol. 1995;191:192-203.
14. Weiss M, Loprinzi CL, Creagan ET, et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA. 1995;274(21):1703-1705.
15. Wang TS, Johnson TM, Cascade PN, et al. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. J Am Acad Dermatol. 2004;51(3):399-405.
16. Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localized primary cutaneous melanoma. Lancet Oncol. 2005;6:608-621.
17. Weinstock MA, Risica PM, Martin RA, et al. Melanoma early detection with thorough skin self-examination: the check it out randomized trial. Am J Prev Med. 2007;32(6)517-524.
18. Hofmann U, Szedlak M, Rittgen W, et al. Primary staging and follow-up in melanoma patients: monocenter evaluation of methods, cost and patient survival. Br J Cancer. 200;87:151-157.
19. Hengge Ur, Wallerand A, Stutzki A, Kockel N. Cost-effectiveness of reduced follow-up in malignant melanoma. J Dtsch Dermatol Ges. 2007;5(10):898-907.
20. Crowley NJ, Siegler HF. Late recurrence of malignant melanoma: analysis of 168 patients. Ann Surg. 1990;212:173-177.
21. DiFronzo LA, Wanek LA, Morton DL. Earlier diagnosis of second primary melanoma confirms the benefits of patient education and routine postoperative follow-up. Cancer. 2001;91(8):1520-1524.
22. Kelly JW, Blois MS, Sagebiel RW. Frequency and duration of patient follow-up after treatment of a primary malignant melanoma. J Am Acad Dermatol. 1985;13 (5 Pt 1):756-760.
23. Miliotis G, Cruse W, Puleo C, et al. The evaluation of new putative markers for melanoma (abstr). Presented at: Forty-Seventh Annual Cancer Symposium of the Society of Surgical Oncology; 1994:169.
24. Garbe C, Leiter U, Ellwanger U, et al. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MArT-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer. 2003;97(7):1737-1745.
25. Mocellin S, Zavagno G, Nitti D. The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis. Int J Cancer. 2008;123(10):2370-2376.
26. Garbe C, Paul A, Kohler-Spath H, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21:520-529.
27. Tsao H, Feldman M, Fullerton JE, et al. Early detection of asymptomatic pulmonary melanoma metastases by routine chest radiographs is not associated with improved survival. Arch Dermatol. 2004;140:67-70.
28. Kuvshinoff BW, Kurtz C, Coit DG. Computed tomography in the evaluation of patients with stage III melanoma (abstr). Forty-Ninth Annual Cancer Symposium of the Society of Surgical Oncology; 1996: 29.
29. Brountzos EN, Panagiotou IE, Bafaloukos DI, Kelekis DA. Ultrasonographic detection of regional lymph node metastases in patients with intermediate or thick malignant melanoma. Oncol Rep. 2003;10:505-510.
30. Schmidt-Wendtner MH, Paerschke G, Baumert J, et al. value of ultrasonography compared with physical examination for the detection of locoregional metastases in patients with cutaneous melanoma. Melanoma Res. 2003;13:183-188.
31. Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011;103(2):129-142.
32. Provost N, Marghoob AA, Koft AW, et al. Laboratory tests and imaging studies in patients with cutaneous malignant melanomas: a survey of experienced physicians. J Am Acad Dermatol. 1997;36(5Pt 1):711-720.
33. Brandberg Y, Månsson-Brahme E, Ringborg U, Sjödén PO. Psychological reactions in patients with malignant melanoma. Eur J Cancer. 1995;31A(2):157-162.